MDT
95.61
+0.82%↑
VEEV
300.34
+2.34%↑
A
138.64
-0.03%↓
HQY
89.66
-1.24%↓
PHR.US
22.83
+1.69%↑
MDT
95.61
+0.82%↑
VEEV
300.34
+2.34%↑
A
138.64
-0.03%↓
HQY
89.66
-1.24%↓
PHR.US
22.83
+1.69%↑
MDT
95.61
+0.82%↑
VEEV
300.34
+2.34%↑
A
138.64
-0.03%↓
HQY
89.66
-1.24%↓
PHR.US
22.83
+1.69%↑
MDT
95.61
+0.82%↑
VEEV
300.34
+2.34%↑
A
138.64
-0.03%↓
HQY
89.66
-1.24%↓
PHR.US
22.83
+1.69%↑
MDT
95.61
+0.82%↑
VEEV
300.34
+2.34%↑
A
138.64
-0.03%↓
HQY
89.66
-1.24%↓
PHR.US
22.83
+1.69%↑
24h
Current
Min
8.78
Max
9.03
Income | 26M -26M |
---|---|
Sales | 2.1M 2.1M |
Profit margin | -1,213.57 |
Recommendations | Strong Buy |
---|---|
12 Months Forecast | +70.45% upside |
Next Earnings | 4 Nov 2025 |
---|
Market Cap | 377M |
---|---|
Previous open | 6.92 |
Previous close | 8.97 |
Past performance is not a reliable indicator of future results.
8 May 2025, 19:14 UTC
Verastem Ovarian-Cancer Drug Combination Gets FDA Approval -- Update
DJ
Read
31 Dec 2024, 19:15 UTC
Verastem Shares Soar on FDA Priority Review of Cancer Treatment
DJ
Read
Price change
By TipRanks
12 Months Forecast
Average 15 USD 70.45%
High 20 USD
Low 13 USD
Based on 5 Wall Street analysts offering 12 month price targets forVerastem Inc - Dist in the last 3 months.
By TipRanks
Strong Buy
5 ratings
5
Buy
0
Hold
0
Sell
Based on 5 analysts giving stock ratings to Verastem Inc - Dist in the past 3 months.
Selling and administration expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$